Provided by Tiger Trade Technology Pte. Ltd.

Armata Pharmaceuticals, Inc.

4.17
+0.10302.53%
Volume:76.27K
Turnover:322.02K
Market Cap:155.16M
PE:-0.79
High:4.32
Open:4.32
Low:4.09
Close:4.07
52wk High:16.34
52wk Low:2.92
Shares:37.18M
Float Shares:11.88M
Volume Ratio:0.15
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2744
EPS(LYR):-4.8000
ROE:-3439.35%
ROA:-25.83%
PB:-0.67
PE(LYR):-0.87

Loading ...

Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial Treatment

Dow Jones
·
Sep 14

Armata Says FDA Grants Breakthrough Therapy Designation for AP-SA02 in Complicated Staph Aureus Bacteremia

Reuters
·
Sep 14

Armata Pharmaceuticals, - to Initiate Phase 3 Superiority Study of AP-Sa02 in H2 2026

THOMSON REUTERS
·
Sep 14

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-Sa02

THOMSON REUTERS
·
Sep 14

Armata Pharmaceuticals CEO Deborah Birx Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 10

Armata Says Inhaled Phage Candidate AP-PA02 Completes Phase 2 Trials in Cystic Fibrosis, Bronchiectasis Patients

Reuters
·
Sep 03

Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate

Benzinga Earnings
·
Aug 13

Armata Swings to FY26 Q2 Net Income of $74.14 Million; Operating Loss Widens to $10.31 Million

Reuters
·
Aug 13

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

THOMSON REUTERS
·
Aug 13

Armata Pharmaceuticals, - Promotes David House to Chief Financial Officer

THOMSON REUTERS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP)

TIPRANKS
·
Jul 20

Armata Pharmaceuticals - Appoints David House as Chief Financial Officer Effective July 17, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 20

Armata provides update on AP-SA02 studies

TIPRANKS
·
Jul 20

Armata Pharmaceuticals Names David House CFO

Reuters
·
Jul 20

Armata Pharmaceuticals Announces Press Release Availability

Reuters
·
Jul 13

Armata Wins FDA Agreement on Pediatric Study Plan for Ap-sa02 in Complicated S. Aureus Bacteremia

Reuters
·
Jul 13

Armata Pharmaceuticals - Adult Phase 3 Study for Ap-sa02 Expected to Initiate in Second Half of 2026

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for Ap-sa02 for the Treatment of Complicated Staphylococcus Aureus Bacteremia

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals - FDA Defers Pediatric Studies for Ap-sa02 Until Adult Phase 3 Data Generated

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals - FDA Agreement Establishes Regulatory Framework for Ap-sa02 in Pediatric SAB

THOMSON REUTERS
·
Jul 13